• Explore /
  • Poster
  • / SAVE (Safe Accelerated Venetoclax Escalation): Initial results of a prospective, phase Ib study of venetoclax with an accelerated dose ramp-up in patients with CLL.

SAVE (Safe Accelerated Venetoclax Escalation): Initial results of a prospective, phase Ib study of venetoclax with an accelerated dose ramp-up in patients with CLL.

Abstract Poster

Authors

null

Jennifer Leigh Crombie

Dana-Farber Cancer Institute, Boston, MA

Jennifer Leigh Crombie , Inhye E Ahn , Svitlana Tyekucheva , Reid Merryman , David Christopher Fisher , Philippe Armand , Josie Montegaard , Marykate Kilcommons , Celeste Carey , Robert Black , Jennifer R. Brown , Matthew Steven Davids

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Chronic Lymphocytic Leukemia (CLL) and Hairy Cell

Clinical Trial Registration Number

NCT04843904

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 7512)

DOI

10.1200/JCO.2023.41.16_suppl.7512

Abstract #

7512

Poster Bd #

63

Abstract Disclosures

Similar Posters

First Author: Mazyar Shadman

First Author: Sudhir Manda

First Author: Rajat Bannerji

Poster

2020 ASCO Virtual Scientific Program

Ten-day decitabine with venetoclax (DEC10-VEN) in AML and high-risk (HR) MDS.

Ten-day decitabine with venetoclax (DEC10-VEN) in AML and high-risk (HR) MDS.

First Author: Abhishek Maiti